Pembrolizumab: First Global Approval

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

(2017) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Update on Immune Checkpoint Inhibitors in Lung Cancer

(2017) Benjamin C. Creelan   Cancer Control

A Review of Novel Therapies for Melanoma

(2014) Chante Karimkhani et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Targeting the PD-1 pathway: a promising future for the treatment of melanoma

(2014) Andrew Mamalis et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Immune Checkpoint Inhibitors in NSCLC

(2014) Douglas B. Johnson et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types

(2013) P. A. Ascierto et al.   CLINICAL CANCER RESEARCH

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Programmed Death 1 Pathway inhibition in Metastatic Renal Cell Cancer and Prostate Cancer

(2012) Patricia A. Tang et al.   Current Oncology Reports